Construction and Validation of a Prediction Model for All - Cause Mortality Within 30 Days After Surgery in Critically Ill Patients Undergoing Emergency Gastrointestinal Surgery
Launched by QUAN WANG · Jan 16, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on creating and testing a new model to predict the risk of death within 30 days after emergency gastrointestinal surgery. These surgeries are important for treating serious digestive issues but can lead to complications like infections, which can be very dangerous. Current methods for predicting the risk of death after such surgeries are not very effective, especially for critically ill patients. By developing a better prediction model, the researchers hope to help doctors identify high-risk patients early on so they can provide more targeted care.
To participate in this trial, individuals need to be over 18 years old and have undergone emergency gastrointestinal surgery while meeting certain critical health conditions afterward, such as needing help with breathing or having severe heart issues. The study will collect and analyze data from patients in two phases: first, looking back at past surgeries, and then following new patients for a short period after their surgery. This research aims to improve patient outcomes and reduce complications, ultimately enhancing recovery after surgery. Participants will be closely monitored, and their health information will be used to help build a reliable tool for doctors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years old; Underwent emergency gastrointestinal surgery \[referring to the tenth edition of the International Classification of Diseases (ICD - 10)\]; Met any of the following criteria for critically ill patients after surgery: those who still required ventilator - assisted ventilation after the surgery; those who needed norepinephrine infusion at a dose \> 1.0 μg/kg/min and even required combination with other vasopressor drugs to maintain blood pressure; those with severe arrhythmia; those with combined failure of other organ functions.
- Exclusion Criteria:
- • The surgical site is superficial and does not involve the abdominal cavity. Cases with data missing by more than 30%. Patients who died during the operation, or those for whom treatment was terminated or abandoned.
- • Cases complicated with multiple injuries. Patients participating in other clinical studies.
About Quan Wang
Quan Wang is a dedicated clinical trial sponsor committed to advancing medical research and innovation through rigorous and ethical study design. With a focus on enhancing patient outcomes and healthcare solutions, Quan Wang collaborates with leading researchers and institutions to conduct high-quality clinical trials across various therapeutic areas. The organization prioritizes safety, transparency, and compliance with regulatory standards, ensuring that all trials are conducted with the utmost integrity. By fostering partnerships and leveraging cutting-edge technology, Quan Wang aims to contribute significantly to the development of new treatments and therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported